# Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

> **NCT01998542** · PHASE2 · COMPLETED · sponsor: **Mirror Biologics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Cancer of Head and Neck
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** AlloVax
- **BIOLOGICAL:** CRCL
- **BIOLOGICAL:** AlloStim

## Key facts

- **NCT ID:** NCT01998542
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01998542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01998542, "Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01998542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*